Related Experiment Video

Updated: Dec 11, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.4K

Management of familial hypercholesterolaemia in childhood

Uma Ramaswami1, Steve E Humphries2

  • 1Lysosomal Disorders Unit, Royal Free Hospital.

Current Opinion in Pediatrics
|August 25, 2020
PubMed

Insights

Statins are safe and effective for lowering LDL-cholesterol in children with familial hypercholesterolaemia, reducing future cardiovascular disease (CVD) risk. Early treatment from age 10 is recommended, with dosage adjustments to meet targets.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Genetics

Background:

  • Familial hypercholesterolaemia (FH) is a genetic condition causing high LDL-cholesterol (LDL-C).
  • Guidelines recommend statins for children with FH to reduce adult cardiovascular disease (CVD) risk.
  • Reviewing current evidence on statin efficacy and safety in pediatric FH management.

Purpose of the Study:

  • To review recent findings on the efficacy and safety of statin use in children with heterozygous familial hypercholesterolaemia.
  • To assess the impact of statins on LDL-C levels and long-term CVD risk in pediatric patients.
  • To discuss factors influencing treatment adherence and genetic determinants of statin response.

Main Methods:

  • Literature review of recent studies on statin therapy in pediatric FH.
  • Analysis of short-term and long-term trial data regarding efficacy and safety.
  • Examination of factors affecting adherence and genetic influences on LDL-C reduction.

Main Results:

  • Statin use in children shows no adverse effects on growth, pubertal development, or muscle/liver toxicity.
  • Long-term follow-up demonstrates reduced CVD rates in children treated with statins.
  • Adherence factors and genetic variations influence LDL-C-lowering effects.

Conclusions:

  • Clinicians should consider statin prescription for children with FH from age 10, or earlier if CVD risk is high.
  • Uptitration of statin dosage and combination therapy are recommended to achieve target LDL-C levels.
  • Statin therapy is a safe and effective strategy for managing pediatric FH and mitigating long-term CVD risk.
Abstract

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.2K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
246
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.1K
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
510
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
335